Across disease types, FGFR1-4 SVs and REs were most commonly observed in bladder cancer (SVs: 1082/7739, 14.0%; REs: 220/7739, 2.8%), urinary tract cancer (SVs: 122/850, 14.4%; REs: 22/850, 2.6%), cholangiocarcinoma (SVs: 181/7729, 2.3%; REs: 668/7729, 8.6%), and endometrial cancers (SVs: 869/11 101, 7.8%; REs: 63/11 101, 0.6%); in bladder cancer, urinary tract cancer, and endometrial cancer, these were mostly SVs, whereas in cholangiocarcinoma, REs were the predominant FGFR genomic alteration (Figure 1). This evidence concerns the gene FGFR1 and cholangiocarcinoma.